On February 9, 2026, the National Institute for Health and Care Excellence (NICE) announced the launch of the new National Healthtech Access Programme (NHAP). The NHAP will expand NICE’s Technology Appraisals programme to include health technologies beyond medicines (medical devices, diagnostics, and digital tools), allowing mandatory reimbursement of recommended technologies. The first two NHAP topics are capsule sponge tests for detecting oesophageal cancer and AI tools for identifying prostate and breast cancer.

In February 2026, the Belgian National Institute for Health and Disability Insurance (INAMI/RIZIV) updated the List of implants and invasive medical devices. One new material code was introduced for percutaneous cryoablation of desmoid tumors. Nominative lists of brands were updated as well, with new devices added in cardiovascular, neuromodulation, and orthopedic fields.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of February 09th, we plan to work on 17 projects. Review the complete list of planned activities in this post.

In January 2026, the National Institute for Health and Care Research (NIHR) in England released three Med Tech-related assessments in its HTA Journal, which concerned digital technologies for chronic tic disorders and Tourette Syndrome, bariatric surgical interventions for severe obesity, and laparoscopic surgery and medical treatment for deep endometriosis.

The French National Authority for Health (HAS) released new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following the January 2026 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). A favourable opinion was issued on the add-on reimbursement for one new device, as well as on the extension of indications for two devices for transcatheter aortic valve implantation.

The appointment of Ms. Giselle Balaciano marks a significant milestone in strengthening MTRC’s expertise in evidence generation and health technology assessment. Her extensive experience in HTA methodology, guideline development, and systematic reviews enhances MTRC’s ability to deliver robust, decision-ready evidence for market access and policy-making. With a proven track record of influencing national healthcare decisions and global methodological leadership, she brings unique strategic value to MTRC’s clients and partners. This reinforces MTRC’s role as a leading provider of high-impact evidence solutions across diverse healthcare systems and therapeutic areas.

In January 2026, the evaluation phase of the “New Methods” framework was completed for real-time and intermittently scanned (flash) continuous glucose monitoring in type 2 diabetes. As the recommendations from HTA are now available, the Decision Forum needs to make a coverage decision for these technologies.

In January 2026, the Dutch Organization for Health Research and Development (ZonMw) awarded fourteen projects under the “Implementation round 3” of the Efficiency Research program, including the MedTech projects in e-health, gastrointestinal, oncology, neurosurgery, IVD, and cardiovascular fields.

In January 2026, the National Institute for Health and Care Excellence (NICE) published three new HealthTech Guidances (HTGs) on balloon cryoablation for Barrett's esophagus, digital self-help technologies for eating disorders, and digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis.

On January 13, 2026, a new version of the Nomenclature of Medical Biology Procedures (NABM 101) was published in France. A new chapter for constitutional genetics was introduced, including two new codes.

In January 2026, the UK National Screening Committee (UK NSC) published details of EquipoISE, a new framework to help evaluate whether multiple additional rare conditions could be added to the UK Newborn Blood Spot (NBS) Screening Programme. EquipoISE is designed as a rolling multi-condition in-service evaluation that works within the existing NHS screening pathway to answer key questions about test performance, clinical outcomes, and feasibility in real-world NHS settings.

In January 2026, the HTA Coordination Group published the report on Emerging Health Technologies identified in 2025 within the framework of the EU Regulation on Health Technology Assessment (HTAR). The report provides information on technologies (including 15 medical devices) that may be eligible for Joint Clinical Assessments (JCAs) at the EU level from 2026.